AI Therapeutics Announces Positive Results from Phase 2a Biomarker-driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis (ALS)
05 avr. 2023 08h00 HE
|
AI Therapeutics, Inc.
Significant reduction of toxic protein aggregate, Poly(GP) Significant increase in biomarker of target engagement, sGPNMB AIT-101 and active metabolites crossed the blood-brain barrier ...
AB Science annonce avoir répondu aux questions au D120 de la procédure EMA de demande d’autorisation conditionnelle du masitinib dans la sclérose latérale amyotrophique et précise le nouveau calendrier de réponse à Santé Canada
04 avr. 2023 12h10 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE AVOIR REPONDU AUX QUESTIONS AU D120 DE LA PROCEDURE EMA DE DEMANDE D’AUTORISATION CONDITIONNELLE DU MASITINIB DANS LA SCLEROSE LATERALE AMYOTROPHIQUE ET...
AB Science announces that it has submitted its response to the day 120 questions in the EMA regulatory review of masitinib in amyotrophic lateral sclerosis and clarifies the new timeline for responding to Health Canada
04 avr. 2023 12h10 HE
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES THAT IT HAS SUBMITTED ITS RESPONSE TO THE DAY 120 QUESTIONS IN THE EMA REGULATORY REVIEW OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AND CLARIFIES THE NEW...
Muscular Dystrophy Association Announces Recipient of 2023 MDA Legacy Award for Achievement in Clinical Research is Merit Cudkowicz, MD, MSC, Renowned Neurologist and Clinical Researcher in ALS
06 mars 2023 09h00 HE
|
Muscular Dystrophy Association
New York, NY, March 06, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Merit Cudkowicz, MD, MSC, a renowned neurologist and clinical researcher in ALS (amyotrophic...
Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity
13 févr. 2023 07h00 HE
|
Clene Inc.
MRI results reinforce the clinical neurological improvements previously reportedMRI results showed improved brain neuronal structural integrity, independent of an immunomodulatory effectMRI results...
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
07 févr. 2023 07h00 HE
|
AC Immune SA
AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43 The Michael J. Fox Foundation grant supports the development of AC Immune’s first-in-class TDP-43 PET tracer...
Muscular Dystrophy Association Awards Venture Philanthropy Funding to PathMaker Neurosystems to Develop Neuromodulation Treatment for ALS
17 janv. 2023 06h00 HE
|
PathMaker Neurosystems Inc.
BOSTON and NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) and PathMaker Neurosystems Inc. (“PathMaker”), a near-commercial stage neuromodulation company...
Major investment in top talent in ALS research
24 nov. 2022 09h00 HE
|
ALS Society of Canada
Toronto, ON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- The ALS Society of Canada (ALS Canada) and Brain Canada are powering innovative discoveries and treatments for amyotrophic lateral sclerosis (ALS)...
AB Science annonce avoir déposé une demande d'autorisation de mise sur le marché conditionnelle auprès de l’EMA pour le masitinib dans le traitement de la SLA
24 août 2022 13h07 HE
|
AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE AVOIR DÉPOSÉ UNE DEMANDE D'AUTORISATION DE MISE SUR LE MARCHÉ POUR ALSITEK DANS LE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE (SLA) QUI A ÉTÉ...
AB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALS
24 août 2022 13h07 HE
|
AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES FILING OF MARKETING AUTHORIZATION APPLICATION FOR ALSITEK IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND ITS VALIDATION BY THE EUROPEAN...